Zoetis Inc. (NYSE:ZTS) Shares Purchased by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 2.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 162,808 shares of the company's stock after purchasing an additional 4,522 shares during the period. Bahl & Gaynor Inc.'s holdings in Zoetis were worth $26,526,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Charles Schwab Investment Management Inc. increased its position in shares of Zoetis by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,394,355 shares of the company's stock valued at $553,042,000 after buying an additional 39,448 shares in the last quarter. Schechter Investment Advisors LLC grew its holdings in Zoetis by 14.2% during the 4th quarter. Schechter Investment Advisors LLC now owns 13,186 shares of the company's stock valued at $2,148,000 after buying an additional 1,641 shares during the last quarter. Meridian Wealth Management LLC increased its position in Zoetis by 10.7% during the fourth quarter. Meridian Wealth Management LLC now owns 1,645 shares of the company's stock worth $268,000 after buying an additional 159 shares in the last quarter. Mission Wealth Management LP raised its holdings in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after acquiring an additional 59 shares during the last quarter. Finally, Fidelis Capital Partners LLC lifted its position in shares of Zoetis by 5.6% in the fourth quarter. Fidelis Capital Partners LLC now owns 5,969 shares of the company's stock valued at $1,026,000 after acquiring an additional 317 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have issued reports on ZTS shares. Piper Sandler upped their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Finally, StockNews.com downgraded Zoetis from a "buy" rating to a "hold" rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $215.90.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

Zoetis Trading Up 1.8 %

Zoetis stock traded up $3.09 during midday trading on Friday, reaching $170.34. The stock had a trading volume of 3,296,788 shares, compared to its average volume of 3,274,650. The stock's 50-day simple moving average is $166.61 and its 200 day simple moving average is $176.92. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market capitalization of $76.28 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis's payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.